Previous Close | 14.71 |
Open | 14.71 |
Bid | 14.70 x 300 |
Ask | 14.72 x 200 |
Day's Range | 14.71 - 14.73 |
52 Week Range | 11.53 - 15.89 |
Volume | |
Avg. Volume | 131,558 |
Market Cap | 213.763M |
Beta (5Y Monthly) | 1.43 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.08 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 13, 2019 |
1y Target Est | N/A |
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...